- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02620163
Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
March 7, 2019 updated by: Yuhan Corporation
A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment
To evaluate efficacy and safety of YH22162 versus telmisartan / amlodipine treatment in patients with hypertension inappropriately controlled on telmisartan/amlodipine treatment
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
381
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Yuhan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed Informed Consent
- Men and women ≥ 19 years of age
Essential hypertensive patients
- If already taking antihypertensive drugs, mean sitting systolic blood pressure (MSSBP) must be 140 mmHg ≤ MSSBP < 200 mmHg
- If not taking any antihypertensive drugs at least 4 weeks, mean sitting systolic blood pressure (MSSBP) must be 160 mmHg ≤ MSSBP < 200 mmHg
Exclusion Criteria:
- Patients with known or suspected secondary hypertension
- Other exclusions applied
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: YH22162
YH22162 40/5/12.5 mg (telmisartan 40/amlodipine 5mg/chlorthalidone 12.5mg) for the first 2 weeks, then force titrated to YH22162(telmisartan 80mg/amlodipine 5mg/chlorthalidone 25mg) for the remaining 6weeks
|
Other Names:
Other Names:
Other Names:
Other Names:
|
Active Comparator: telmisartan/amlodipine
Twynsta(telmisartan 40/amlodipine 5mg) for the first 2 weeks, then force titrated to Twynsta(telmisartan 80mg/amlodipine 5mg) for the remaining 6weeks
|
Other Names:
Other Names:
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8
Time Frame: baseline and week 8
|
baseline and week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 2
Time Frame: baseline and week 2
|
baseline and week 2
|
|
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4
Time Frame: baseline and week 4
|
baseline and week 4
|
|
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 2
Time Frame: baseline and week 2
|
baseline and week 2
|
|
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 4
Time Frame: baseline and week 4
|
baseline and week 4
|
|
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSSBP) at Week 8
Time Frame: baseline and week 8
|
baseline and week 8
|
|
Patients Achieving Blood Pressure Control at Week 2
Time Frame: baseline and week 2
|
Mean sitting blood pressure(MSBP) < 140/90 mmHg
|
baseline and week 2
|
Patients Achieving Blood Pressure Control at Week 4
Time Frame: baseline and week 4
|
Mean sitting blood pressure(MSBP) < 140/90 mmHg
|
baseline and week 4
|
Patients Achieving Blood Pressure Control at Week 8
Time Frame: baseline and week 8
|
Mean sitting blood pressure(MSBP) < 140/90 mmHg
|
baseline and week 8
|
Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 2
Time Frame: baseline and week 2
|
reduction of MSSBP>= 20 mmHg and reduction of MSSBP>= 10 mmHg
|
baseline and week 2
|
Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 4
Time Frame: baseline and week 4
|
reduction of MSSBP>= 20 mmHg and reduction of MSSBP>= 10 mmHg
|
baseline and week 4
|
Reduction From Baseline in Mean Sitting Blood Pressure (MSBP) at Week 8
Time Frame: baseline and week 8
|
reduction of MSSBP>= 20 mmHg and reduction of MSSBP>= 10 mmHg
|
baseline and week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Hyunhee Na, MD, Yuhan Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2015
Primary Completion (Actual)
December 1, 2016
Study Completion (Actual)
December 1, 2016
Study Registration Dates
First Submitted
November 28, 2015
First Submitted That Met QC Criteria
November 29, 2015
First Posted (Estimate)
December 2, 2015
Study Record Updates
Last Update Posted (Actual)
March 11, 2019
Last Update Submitted That Met QC Criteria
March 7, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Chloride Symporter Inhibitors
- Amlodipine
- Chlorthalidone
- Telmisartan
- Telmisartan amlodipine combination
Other Study ID Numbers
- YH22162-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on YH22162 40/5/12.5 mg
-
Edgewise Therapeutics, Inc.Medpace, Inc.; SYSNAV; ImagingNMDRecruitingBecker Muscular DystrophyUnited States, Netherlands, United Kingdom
-
Boehringer IngelheimEli Lilly and CompanyCompleted
-
AstraZenecaCompletedStudy to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male SubjectsRefluxNetherlands, Belgium
-
Janssen Pharmaceutical K.K.Completed
-
Yuhan CorporationNot yet recruitingEssential HypertensionKorea, Republic of
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Menarini GroupDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyCompletedHypertensionPoland, Germany, Israel, Romania, Italy, Denmark, Czechia, Croatia
-
Janssen-Cilag International NVCompleted